Children's Oncology Group
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Children's Oncology Group sits in the top decile of US sponsors by registered trial count (#104 of 15,742 sponsors by registered trial count).
Children's Oncology Group: 342 sponsored US clinical trials, 33 recruiting.
Children's Oncology Group sponsors 342 registered US clinical trials on ClinicalTrials.gov, 33 of them currently recruiting, and 260 completed. 103 of these trials are in Phase 3-4 (later-stage) and 128 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 12 trials.
Top-decile sponsor footprint
Children's Oncology Group ranks in the top decile of sponsors by registered trial count (#104 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
260 of 262 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (99.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
342 total, page 2 of 7
Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH)
NCT04100408
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
NCT04158739
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
NCT03817398
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
NCT03834961
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT03794349
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03533582
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
NCT03057054
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
NCT03223753
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
NCT02724579
Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma
NCT03296371
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
NCT03057626
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
NCT03033992
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02521493
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
NCT02339740
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02176967
Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy
NCT01503086
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
NCT01503632
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
NCT01190930
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
NCT01096368
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group
NCT01117168
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
NCT00945009
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
NCT00772200
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
NCT00392327
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
NCT00379340
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
NCT00352534
Study of Kidney Tumors in Younger Patients
NCT00898365
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
NCT00107198
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
NCT00082745
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
NCT03792256
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
NCT03320330
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
NCT03323034
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
NCT03204916
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
NCT03206450
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT02975882
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
NCT02900976
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT02808650
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
NCT02847130
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02642965
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
NCT01567046
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
NCT02717507
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
NCT02470091
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
NCT02323880
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
NCT02452554
Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
NCT02097134
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
NCT02164838
Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma
NCT02017964
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
NCT01817075
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
NCT01824693
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 75 |
| Phase 3 | 103 |
Therapeutic Areas
What is open in the Children's Oncology Group pipeline
33 recruiting of 342 indexed (10% open); 260 completed (76%).
Phase mix: 103 late (III/IV) vs 128 early (I/II) (balanced across stages).
Top condition: Leukemia (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Children's Oncology Group: open-pipeline peers nationwide
Peers matched on 342 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Children's Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 342 trials (± recruiting share)
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
- Ohio State University Comprehensive Cancer Center · 341 trials · 23% recruiting
- Montefiore Medical Center · 345 trials · 19% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Children's Hospitals and Clinics of Minnesota · 10% recruiting · 31 trials
- Cytokinetics · 10% recruiting · 31 trials
- Sanofi · 10% recruiting · 713 trials
- Joslin Diabetes Center · 10% recruiting · 73 trials
Related
What to do with this Children's Oncology Group page
342 registered trials is a research-attention snapshot, not an endorsement of Children's Oncology Group or any single study.
- 33 of Children's Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Leukemia is the condition Children's Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Children's Oncology Group pipeline card: 342 registered trials from official public datasets.Report a data error.